News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic reports positive long-term data from phase 2 EMPhASIS Trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosis, showing favorable safety & tolerability profile up to 5.5 years -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026
